1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 56 pages

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma – Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Metastatic Uveal Melanoma - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Uveal Melanoma Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Uveal Melanoma - Overview 7
Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis 8
Metastatic Uveal Melanoma - Therapeutics under Development by Companies 9
Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 10
Metastatic Uveal Melanoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Metastatic Uveal Melanoma - Products under Development by Companies 13
Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes 14
Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development 15
Bellicum Pharmaceuticals Inc 15
Celldex Therapeutics Inc 16
Eli Lilly and Company 17
Novartis AG 18
Spectrum Pharmaceuticals Inc 19
Metastatic Uveal Melanoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
alpelisib - Drug Profile 29
Product Description 29
Mechanism Of Action 29
RandD Progress 29
BPX-701 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
RandD Progress 32
emibetuzumab - Drug Profile 34
Product Description 34
Mechanism Of Action 34
RandD Progress 34
glembatumumab vedotin - Drug Profile 36
Product Description 36
Mechanism Of Action 36
RandD Progress 36
KCN-1 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
RandD Progress 40
LXS-196 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
RandD Progress 41
merestinib - Drug Profile 42
Product Description 42
Mechanism Of Action 42
RandD Progress 42
sotrastaurin acetate - Drug Profile 44
Product Description 44
Mechanism Of Action 44
RandD Progress 44
vincristine sulfate - Drug Profile 46
Product Description 46
Mechanism Of Action 46
RandD Progress 46
Metastatic Uveal Melanoma - Dormant Projects 51
Metastatic Uveal Melanoma - Discontinued Products 52
Metastatic Uveal Melanoma - Product Development Milestones 53
Featured News and Press Releases 53
Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 53
Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56




List of Tables
Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7
Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Metastatic Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 15
Metastatic Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016 16
Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016 17
Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2016 18
Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Metastatic Uveal Melanoma - Dormant Projects, H2 2016 51
Metastatic Uveal Melanoma - Discontinued Products, H2 2016 52




List of Figures
Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7
Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Targets, H2 2016 21
Number of Products by Stage and Targets, H2 2016 21
Number of Products by Top 10 Mechanism of Actions, H2 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Types, H2 2016 27

Companies Mentioned
Bellicum Pharmaceuticals Inc
Celldex Therapeutics Inc
Eli Lilly and Company
Novartis AG
Spectrum Pharmaceuticals Inc

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) ...

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2016

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.